n°156 | November 30, 2021
In this issue:

EU "needs to recognise progress of PSA screening"

Prominent MEP calls for inclusion of targeted prostate screening in Beating Cancer plan
29 Nov 2021

Quality of life studies may "reduce treatment decision regret"

European Urology Focus report on EUPROMS emphasises importance of such studies
22 Nov 2021

EU screening should change significantly

European Cancer Organisation urges improvements in early detection of prostate cancer
18 Nov 2021

EUPROMS 2.0: please use our publicity resources

Europa Uomo Chairman urges groups to encourage more responses
6 Nov 2021
Prostate Research and Treatments

EAU Podcasts: 'New guideline recommendations on prostate cancer'

In these two podcasts Prof. Mottet discusses the most important changes in the new EAU Guidelines for Prostate Cancer treatment:

In part 1, Prof. Nicolas Mottet talks about the most important changes in the new EAU Guidelines for Prostate Cancer treatment and discusses in more detail perineal biopsy, staging PSMA, adjuvant Radio Therapy.

In part 2, Prof. Nicolas Mottet discusses which are the most important changes in the new EAU Guidelines for Prostate Cancer treatment related to genetic testing, M1 disease and Castration-resistant prostate cancer (CRPC).

Europa Uomo News


Dear Reader,

The EUPROMS 2.0 survey will be open until 23rd December 2021 . We launched the survey on 25th October, so we are about halfway through the response period.

We have 2000 completed questionnaires so far, which is pretty much in line with replies at the same stage to our first EUPROMS survey. The most completed surveys have come from the Netherlands and Norway.

We learned from the first EUPROMS study that the final weeks are important if we want to reach our target response rate. Now is the time to repeat your mailings and announcements to your members.

I do not need to remind you how important this survey is. We would like to present the results to the European Commission before it decides on cancer early detection plans for the next five to six years.

As you can read in another item in this issue, that announcement is expected early next year. I understand that early detection of prostate cancer is included In the latest draft, but the battle is not won until the text is final and signed by the Commission.

Therefore it is essential that we raise our voice and keep doing so until the finish. Once early detection is agreed in the European Cancer Plan, the next challenge is ensuring it is implemented in each country.

That is where our survey can create awareness about the burden of prostate cancer. The more responses we have from your country, the more your politicians and decision makers will listen.

Do not miss this opportunity. If you give us the data, we will supply you with analysis and materials that you can use.

Thanks for your efforts so far, and please keep going.

André Deschamps, Chairman

Europa Uomo withdraws membership from ECPC

Dear Reader,

On Saturday 27th November, Europa Uomo attended the European Cancer Patient Coalition (ECPC) General Assembly. It is with great regret that we have to announce that, after this meeting, the Europa Uomo Board decided to withdraw its membership from ECPC with immediate effect. We will advice our members to do the same.

For the first time in years, the ECPC board presented full accounts and proposed sound action plans. But, the General Assembly has voted against.

This was mainly due to an orchestrated “vote against everything proposed by the board” and had nothing to do with the content of the action plans nor the accuracy of the accounts.

This action leaves the organisation powerless and in disarray. We do not believe that this situation will change in the near future.

What has happened is not in the interests of cancer patients in Europe.

Europa Uomo will support any new initiative which attempts to properly represent all cancer patients in Europe.

André Deschamps, Chairman Europa Uomo

Items of Interest

The future of Active Surveillance

The Developing Provocative Questions: The Prostate Cancer Active Surveillance Research Initiative is a 2-day virtual conference brought to you by the University of Maryland and others. It is designed as a consensus-building initiative across multiple stakeholder groups (patients, clinicians, and academic researchers) to bring the communities together and discuss – in a structured way – challenges associated with the clinical use of active surveillance (AS) in management of favorable-risk forms of prostate cancer, and to identify a prioritized list of unanswered questions in the so-called PICOT (Population, Intervention, Comparison, Outcome, and Time) format.

The program, “Developing Provocative Questions: The Prostate Cancer Active Surveillance Research Initiative,”  will be held  from 6-10:00 pm CET time on Monday, December 13 AND on Thursday, December 16.

Registration is limited so reserve your seat. Go to: https://tinyurl.com/DPQ-PCASRI 

Webinar: 'Anxious Surveillance: Coping with Anxiety and Active Surveillance'


All previous issues are available on website: www.europa-uomo.org/newsletters/